Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Investigate the Efficacy and Safety of LN-OS-22 on Oxidative Stress and Systemic Inflammation in Overweight and Obese Population.

NCT05404217 is registered in ClinicalTrials.gov with Vedic Lifesciences Pvt. Ltd. as lead sponsor.

NCT NCT05404217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05404217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Investigate the Efficacy and Safety of LN-OS-22 on Oxidative Stress and Systemic Inflammation in Overweight and Obese Population.
Lead sponsor
Vedic Lifesciences Pvt. Ltd.
Phase
Not applicable
Overall status
Completed
Start date
June 16, 2022
Completion date
March 13, 2023
Enrollment
64 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

oxidative stress